{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:12:05Z","timestamp":1783037525873,"version":"3.54.6"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["TMDU 2023"],"award-info":[{"award-number":["TMDU 2023"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21gm0010008h0001"],"award-info":[{"award-number":["21gm0010008h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["223fa827006h0001"],"award-info":[{"award-number":["223fa827006h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21fk0108620h0001"],"award-info":[{"award-number":["21fk0108620h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJPF2022"],"award-info":[{"award-number":["JPMJPF2022"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24390403"],"award-info":[{"award-number":["24390403"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15H05008"],"award-info":[{"award-number":["15H05008"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H04962"],"award-info":[{"award-number":["21H04962"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H03529"],"award-info":[{"award-number":["18H03529"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K1748"],"award-info":[{"award-number":["23K1748"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H02905"],"award-info":[{"award-number":["18H02905"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["26670791"],"award-info":[{"award-number":["26670791"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H03176"],"award-info":[{"award-number":["22H03176"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jconrel.2025.113860","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T19:09:45Z","timestamp":1747422585000},"page":"113860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Highly pure mRNA vaccine provides robust immunization against P. aeruginosa by minimizing type I interferon responses"],"prefix":"10.1016","volume":"383","author":[{"given":"Ken","family":"Kawaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Bui Thao","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teiji","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.113860_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114000","article-title":"Messenger RNA-based vaccines: past, present, and future directions in the context of the COVID-19 pandemic","volume":"179","author":"Jain","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113860_bb0010","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113860_bb0015","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.113860_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15476286.2024.2333123","article-title":"mRNA vaccine designs for optimal adjuvanticity and delivery","volume":"21","author":"Mochida","year":"2024","journal-title":"RNA Biol."},{"key":"10.1016\/j.jconrel.2025.113860_bb0025","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.113860_bb0030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.113860_bb0035","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113860_bb0040","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113860_bb0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/d41586-023-00220-z","article-title":"The next generation of coronavirus vaccines: a graphical guide","volume":"614","author":"Callaway","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.113860_bb0050","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Conquer, efficacy and safety of an mRNA-based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113860_bb0055","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/infdis\/jiad593","article-title":"Human cytomegalovirus mRNA-1647 vaccine candidate elicits potent and broad neutralization and higher antibody-dependent cellular cytotoxicity responses than the gB\/MF59 vaccine","volume":"230","author":"Hu","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2025.113860_bb0060","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1038\/s41467-023-39376-7","article-title":"Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113860_bb0065","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1473-3099(24)00493-6","article-title":"Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A\/H3N2 strains with or without the B\/Yamagata strain in US adults aged 50-75 years: a phase 1\/2, open-label, randomised trial","volume":"25","author":"Hsu","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jconrel.2025.113860_bb0070","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg1036","article-title":"A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium","volume":"9","author":"Kon","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2025.113860_bb0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41541-023-00672-4","article-title":"Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa","volume":"8","author":"Wang","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jconrel.2025.113860_bb0080","article-title":"Antimicrobial resistance at the G7","volume":"373","author":"Glover","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jconrel.2025.113860_bb0085","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fimmu.2020.01048","article-title":"Vaccines against antimicrobial resistance","volume":"11","author":"Rosini","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.113860_bb0090","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","article-title":"The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update","volume":"81","author":"Reynolds","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2025.113860_bb0095","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1586\/14760584.2014.890053","article-title":"Vaccines for Pseudomonas aeruginosa: a long and winding road","volume":"13","author":"Priebe","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.jconrel.2025.113860_bb0100","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/7391","article-title":"Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury","volume":"5","author":"Sawa","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.113860_bb0105","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/1348-0421.12658","article-title":"The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia","volume":"62","author":"Naito","year":"2018","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.jconrel.2025.113860_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2025.113860_bb0115","doi-asserted-by":"crossref","first-page":"18758","DOI":"10.1021\/acsnano.3c02251","article-title":"An ionizable lipid material with a vitamin E scaffold as an mRNA vaccine platform for efficient cytotoxic T cell responses","volume":"17","author":"Oyama","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.113860_bb0120","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41565-023-01404-4","article-title":"Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines","volume":"18","author":"Han","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.113860_bb0125","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1021\/acscentsci.1c00197","article-title":"Modifications in an emergency: the role of N1-methylpseudouridine in COVID-19 vaccines","volume":"7","author":"Nance","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.jconrel.2025.113860_bb0130","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2025.113860_bb0135","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.omtn.2023.05.004","article-title":"The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system","volume":"32","author":"Bernard","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2025.113860_bb0140","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2025.113860_bb0145","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1074\/jbc.270.11.6298","article-title":"Self-coded 3\u2032-extension of run-off transcripts produces aberrant products during in vitro transcription with T7 RNA polymerase","volume":"270","author":"Triana-Alonso","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2025.113860_bb0150","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Kariko","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2025.113860_bb0155","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nprot.2013.019","article-title":"Reprogramming human fibroblasts to pluripotency using modified mRNA","volume":"8","author":"Mandal","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2025.113860_bb0160","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.omtn.2022.01.004","article-title":"Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages","volume":"27","author":"Moradian","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2025.113860_bb0165","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/s41467-023-38244-8","article-title":"Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures","volume":"14","author":"Inagaki","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113860_bb0170","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1073\/pnas.0911587107","article-title":"Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2025.113860_bb0175","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1073\/pnas.94.9.4262","article-title":"A general purpose RNA-cleaving DNAenzyme","volume":"94","author":"Santoro","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2025.113860_bb0180","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2214320120","article-title":"Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment","volume":"120","author":"Tockary","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2025.113860_bb0185","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/CCM.0000000000001271","article-title":"Immunoglobulin for acute lung injury and bacteremia in Pseudomonas aeruginosa pneumonia","volume":"44","author":"Katoh","year":"2016","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.jconrel.2025.113860_bb0190","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-8518-1-2","article-title":"Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model","volume":"1","author":"Faure","year":"2003","journal-title":"J. Immune Based Ther. Vaccines"},{"key":"10.1016\/j.jconrel.2025.113860_bb0195","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/341069","article-title":"Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV","volume":"186","author":"Frank","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jconrel.2025.113860_bb0200","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.ymthe.2024.03.022","article-title":"Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity","volume":"32","author":"Abbasi","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.113860_bb0205","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/infdis\/116.1.112","article-title":"The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. II. Effects of lecithinase and protease","volume":"116","author":"Liu","year":"1966","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2025.113860_bb0210","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.4049\/jimmunol.159.6.2858","article-title":"IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia","volume":"159","author":"Sawa","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2025.113860_bb0215","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/CCM.0000000000001271","article-title":"IV immunoglobulin for acute lung injury and bacteremia in Pseudomonas aeruginosa pneumonia","volume":"44","author":"Katoh","year":"2016","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.jconrel.2025.113860_bb0220","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2025.113860_bb0225","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1021\/acs.molpharmaceut.2c01024","article-title":"Delivery and expression of mRNA in the secondary lymphoid organs drive immune responses to lipid nanoparticle-mRNA vaccines after intramuscular injection","volume":"20","author":"Takanashi","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.113860_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102083","article-title":"mRNA vaccine trafficking and resulting protein expression after intramuscular administration","volume":"35","author":"Hassett","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2025.113860_bb0235","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2012.202","article-title":"Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines","volume":"21","author":"Pollard","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.113860_bb0240","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/mt.2016.161","article-title":"Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses","volume":"24","author":"De Beuckelaer","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.113860_bb0245","article-title":"Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domain","author":"Kobiyama","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.jconrel.2025.113860_bb0250","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2025.113860_bb0255","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.113860_bb0260","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2025.113860_bb0265","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/vaccines7030096","article-title":"Immunogenicity and protection efficacy of a naked self-replicating mRNA-based zika virus vaccine","volume":"7","author":"Zhong","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jconrel.2025.113860_bb0270","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2958.1997.4891851.x","article-title":"ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury","volume":"25","author":"Finck-Barban\u00e7on","year":"1997","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.jconrel.2025.113860_bb0275","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1093\/emboj\/cdg290","article-title":"The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU","volume":"22","author":"Sato","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.jconrel.2025.113860_bb0280","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1097\/01.CCM.0000145588.79063.07","article-title":"Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU","volume":"32","author":"Pankhaniya","year":"2004","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.jconrel.2025.113860_bb0285","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.4161\/21645515.2014.971641","article-title":"Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa","volume":"10","author":"Sawa","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jconrel.2025.113860_bb0290","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1097\/CCM.0b013e31825334f6","article-title":"Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial","volume":"40","author":"Francois","year":"2012","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.jconrel.2025.113860_bb0295","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.tibtech.2022.03.012","article-title":"Quality by design for enabling RNA platform production processes","volume":"40","author":"Daniel","year":"2022","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2025.113860_bb0300","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.omtn.2019.08.001","article-title":"Expression kinetics and innate immune response after electroporation and LNP-mediated delivery of a self-amplifying mRNA in the skin","volume":"17","author":"Huysmans","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2025.113860_bb0305","doi-asserted-by":"crossref","first-page":"28311","DOI":"10.1021\/acsnano.4c09677","article-title":"Amplification of protein expression by self-amplifying mRNA delivered in lipid nanoparticles containing a beta-aminoester ionizable lipid correlates with reduced innate immune activation","volume":"18","author":"De Lombaerde","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.113860_bb0310","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.113860_bb0315","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.omtn.2020.09.004","article-title":"The opposing effect of type I IFN on the T cell response by non-modified mRNA-lipoplex vaccines is determined by the route of administration","volume":"22","author":"Van Hoecke","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2025.113860_bb0320","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.celrep.2019.01.107","article-title":"RIG-I selectively discriminates against 5\u2019-monophosphate RNA","volume":"26","author":"Ren","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.jconrel.2025.113860_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e23595","article-title":"Insufficient anti-spike RBD IgA responses after triple vaccination with intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2","volume":"10","author":"Yoshimura","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2025.113860_bb0330","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.8051","article-title":"Serum and salivary IgG and IgA response after COVID-19 messenger RNA vaccination","volume":"7","author":"Gorochov","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jconrel.2025.113860_bb0335","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adn2364","article-title":"Repeated COVID-19 mRNA-based vaccination contributes to SARS-CoV-2 neutralizing antibody responses in the mucosa","volume":"16","author":"Declercq","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.113860_bb0340","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add4853","article-title":"Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination","volume":"7","author":"Tang","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jconrel.2025.113860_bb0345","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/1348-0421.12147","article-title":"V-antigen homologs in pathogenic gram-negative bacteria","volume":"58","author":"Sawa","year":"2014","journal-title":"Microbiol. Immunol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925004808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925004808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T15:21:09Z","timestamp":1762269669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925004808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":69,"alternative-id":["S0168365925004808"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113860","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highly pure mRNA vaccine provides robust immunization against P. aeruginosa by minimizing type I interferon responses","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113860","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113860"}}